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Résumé en
anglais
Purpose: Fluorine-19 magnetic resonance spectroscopy ( F-MRS) studies of the
pharmacokinetics of the anticancer drug 5-fluorouracil (FU) in patients at several
clinical centres have shown that increased tumour retention of FU is associated with
patient response. The mechanism of this increased tumour retention (FU trapping) is
unknown. We used a pre-clinical model to investigate whether other MRS-measurable
parameters would correlate with the response to FU treatment and, thus, help
elucidate the mechanism(s) involved in FU trapping. Methods: MRS spectra were
obtained using a double-tuned (P-31/F-19) surface coil from 29 N-methyl-N-
nitrosourea-induced primary rat rumours. P-31-MRS spectra were acquired
immediately prior to and at 2.5 h post-treatment with a bolus i.p. injection of FU (100
mg/kg); F-19-MRS spectra were acquired during the intervening 2.5-h period for
measurement of the tumour uptake and retention of FU and of its metabolism to the
cytotoxic fluoronucleotides (FNuct). From these data, four parameters were
measured: tumour pH and energy status (NTP/Pi) before treatment, total FU
retention, and FU anabolism to FNuct (expressed as micromoles per gram per 2.5 h).
In addition, tumour response was determined at 7 days post-treatment by
measurement of the percentage of change in tumour weight and was classified
according to standard oncological criteria as follows: progressive (P) for a 225%
increase, remissive (R) for a greater than or equal to 50% decrease or stable (S) for
values lying between these two. Results: Analysis of variance (ANOVA) for statistical
assessment revealed that groups P, S and R were not distinguishable using the MRS
parameters; although when S and R were combined as one group of non-progressive
disease (NPD; n = 24), both the NTP/Pi ratio and the total FNuct formed were
significantly greater (P = 0.03) than those observed in the P group (Iz = 5).
Considering all 29 tumours, linear regression showed that there were positive
significant correlations between the NTP/Pi ratio and (a) the percentage of response
(P = 0.04), (b) the pre-treatment pH (P = 0.002) and (c) FU retention (P = 0.02), but
not FNuct formation(P = 0.66). Unlike results reported in the clinic, the percentage of
response and FU retention were neither significantly correlated (P = 0.22) nor
associated when groups P and NPD were compared (P = 0.27, Fischer's exact test).
FNuct, however, was significantly associated with response, as was the NTP/Pi ratio
(P less than or equal to 0.02). Combination of FNuct with the NTP/Pi ratio increased
the significance of the association with response (P = 0.003, Fischer's exact test).
Conclusions: Our results indicate that in this particular model the pretreatment
tumour NTP/Pi ratio was the best predictor of response to a bolus injection of FU,
rather than FNuct formation or FU retention. An elevated NTP/Pi ratio could reflect a
well-vascularised tumour with an improved capacity for energy-dependent FU uptake
and metabolism to FNuct, suggesting that further investigation of this parameter
could be an important line of research, which may aid the identification of tumours
likely to be sensitive to FU chemotherapy in the clinic.
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